Table 3.

Forearm muscle protein metabolism components at baseline and after intervention by randomization group

	ω-3 (n=11)	Placebo (n=9)	P Value	Difference Between Groups (95% CI)
Forearm muscle protein metabolism (μg/100 ml per min)
Synthesis
Baseline	68 (52–106)	44 (14–64)	0.08	56 (0.7 to 111)
12 weeks	43 (25–54)	45 (38–65)	0.37	−30 (−96 to 36)
δ	−58 (-102–14)	49 (0.5–54)	0.04	−86 (−167 to −5)
Breakdown
Baseline	73 (37–147)	45 (32–92)	0.26	48 (−20 to 117)
12 weeks	42 (31–58)	88 (60–107)	0.01	−48 (−80 to −16)
δ	−31 (−98–−13)	26 (13–87)	0.01	−97 (−160 to −34)
Net Balance
Baseline	−24 (−34–16)	−17 (-28–−10)	0.94	7 (−26 to 40)
12 weeks	0.6 (−31–19)	−8 (−56–12)	0.50	18 (−42 to 78)
δ	6 (−11–32)	22 (−28–41)	0.97	11 (−70 to 92)
Whole body protein metabolism (mg/kg per fat free mass per min)
Synthesis
Baseline	4.2 (3.6–4.9)	5.5 (4.1–5.8)	0.12	−1.0 (−2.0 to 0.0)
12 weeks	4.0 (3.3–4.7)	4.2 (4.1–4.8)	0.25	−0.5 (−1.1 to 0.2)
δ	−0.08 (−0.72–0.22)	−0.84 (−0.89–−0.01)	0.32	0.5 (−0.3 to 1.4)
Breakdown
Baseline	4.1 (3.5–4.9)	5.5 (4.1–5.7)	0.08	−1.0 (−2.0 to 0.0)
12 weeks	4.1 (3.2–4.6)	4.2 (4.2–4.8)	0.17	−0.5 (−1.1 to 0.1)
δ	−0.04 (−0.77–0.15)	−0.65 (−0.88–0.11)	0.28	0.5 (−0.4 to 1.3)
Net Balance
Baseline	−0.01 (−0.04–0.02)	0.00 (−0.04–0.08)	0.58	0.0 (−0.1 to 0.1)
12 weeks	−0.02 (−0.07–0.14)	−0.07 (−0.11–0.02)	0.10	0.1 (0.0 to 0.2)
δ	−0.04 (−0.09–0.11)	−0.10 (−0.14–0.003)	0.25	0.1 (0.0 to 0.2)

Data are presented as median with interquartile range. Unadjusted P value was estimated with Wilcoxon rank sum test. δ, difference from baseline to 12 weeks.